Analyst Reco. Novartis AG

Equities

Market Closed - Swiss Exchange Other stock markets 11:30:57 2025-12-05 EST			5-day change	1st Jan Change
107.08 ^CHF	+0.19%		+2.49%	+20.72%

01:45pm	Novartis raises guidance and target price after strong execution
11:40pm	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT

Novartis raises guidance and target price after strong execution	11:23am
Sector Update: Health Care Stocks Higher Late Afternoon	12-03	MT
Novartis Shares Rise After Morgan Stanley Upgrade	12-03	MT
Morgan Stanley Upgrades Novartis to Overweight From Equal Weight, $136 Price Target	12-03	MT
Janux dives as gaps in prostate cancer study data worry investors	12-02	RE
Swiss stocks - Factors to watch on November 25	11-25	RE
AlphaValue/Baader Europe Upgrades Novartis to Add Rating, Raises PT	11-21	MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	11-21	ZD
NOVARTIS AG : Gets a Neutral rating from UBS	11-21	ZD
NOVARTIS AG : Barclays reiterates its Sell rating	11-21	ZD
NOVARTIS AG : Bernstein remains its Buy rating	11-21	ZD
NOVARTIS AG : UBS reaffirms its Neutral rating	11-20	ZD
Swiss stocks - Factors to watch on November 20	11-20	RE
Swiss stocks - Factors to watch on November 19	11-19	RE
Berenberg Ups Novartis Price Target Ahead of Capital Markets Day	11-18	MT
NOVARTIS AG : Berenberg reaffirms its Neutral rating	11-18	ZD
NOVARTIS AG : Gets a Neutral rating from JP Morgan	11-12	ZD
Sector Update: Health Care Stocks Advance Late Afternoon	11-10	MT
America's markets lose their nerve	11-07
NOVARTIS AG : UBS is Neutral	11-04	ZD
NOVARTIS : UBS raises target price	11-04
Morgan Stanley upgrades Novartis stock	10-31
Morgan Stanley Upgrades Novartis to Overweight, Lifts PT	10-31	MT
Novartis: stock up again, with Morgan Stanley more optimistic	10-31
NOVARTIS AG : Deutsche Bank remains its Buy rating	10-31	ZD

No results for this search

Novartis raises guidance and target price after strong execution

December 05, 2025 at 11:23 am

Novartis: The Swiss pharmaceutical giant invests in the future

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare